
D9670C00001 | Destiny-Breast06 (DB-06)
NCT04494425
Pending
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Status:
Opening Soon

III
Phase

3rd
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
Trastuzumab Deruxtecan (T-DXd)
Treatment Arms
o Experimental: Trastuzumab deruxtecan
o Active Comparator: Standard of Care